Key things are:
*It reduces tumor size,
*More tumors become operable,
*it extends the life of those treated with it:
*Surgical resection in LAPC is critical, improving the 5-year survival rate from ~5% to >20%...
*Patients undergoing surgical resection had significantly better survival than patients who did not:
median Overall Survival: 35.3 vs. 16.3 months and 3-year survival rate: 50.0% vs. 11.0% (p<0.001).
Ann: OncoSil AGM CEO Presentation, page-16
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.001(14.3%) |
Mkt cap ! $27.18M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.8¢ | 0.7¢ | $149.4K | 19.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 5248000 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 5822684 | 6 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |